Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.Nature Communications|April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanomaAkash Mitra, Miles C Andrews, Whijae Roh, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Cell|November 3, 2018
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in MelanomaMoshe Sade-Feldman, Keren Yizhak, Stacey L Bjorgaard, et al.Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.Nature|April 5, 2016
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceAmanpreet Kaur, Marie R Webster, Katie Marchbank, et al.Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.Pageof 9